Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.
about
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypesPharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Agreement between Patient and Proxy Assessments of Quality of Life among Older Adults with Vascular Cognitive Impairment Using the EQ-5D-3L and ICECAP-OLipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease.Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database.Genetics in clinical trials.The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease.Genomics and proteomics are changing discovery, development and clinical use of dementia drugs.Predictors of comprehensive stimulation program efficacy in patients with cognitive impairment. Clinical practice recommendations.Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer's Patients.
P2860
Q33596451-EF7793D6-B0A7-4907-AAF8-1C0F4FCA38DEQ34019150-DA2FD793-529F-44DB-8214-AA1671FD4878Q34327769-A0A25F1C-FD55-447C-8E28-56D50BFE2B50Q35996331-B1803037-D295-4FC5-A75C-AFECF8E1F63CQ36044934-8CC2187E-E97C-4990-A0E4-92DA00486AE7Q36475090-EEA1C93E-BC05-4B85-8468-0FB009DD2B0CQ37044205-A31E5A11-85C8-44F9-AA0A-ACB6CCF9D46FQ37300216-B84DA03E-5EC9-4DD3-9FEB-464A60112829Q37462565-A95AF070-0D9E-4FFE-A47E-99A8807BBBF7Q37691138-537928FC-62B6-4AA7-B2BF-0759A1E64072Q38088754-2ECF8E42-8465-4290-82FB-9A161A695136Q45745922-50E8AF50-8030-4BAA-A452-BA2538B6718AQ50740022-39C9690B-98CC-4519-831A-721A0BBE1324Q52151010-996F9750-090E-4C1C-8471-8EC8068F4E7F
P2860
Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Differential qualitative respo ...... on 4 carriers and noncarriers.
@en
Differential qualitative respo ...... on 4 carriers and noncarriers.
@nl
type
label
Differential qualitative respo ...... on 4 carriers and noncarriers.
@en
Differential qualitative respo ...... on 4 carriers and noncarriers.
@nl
prefLabel
Differential qualitative respo ...... on 4 carriers and noncarriers.
@en
Differential qualitative respo ...... on 4 carriers and noncarriers.
@nl
P2093
P2860
P356
P1476
Differential qualitative respo ...... on 4 carriers and noncarriers.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.TPJ.6500267
P577
2004-01-01T00:00:00Z
P5875
P6179
1010957977